Exelixis | EXEL - Net Income


Exelixis reported $212.05M in Net Income for its fiscal quarter ending in June of 2026.





Net Income Change Date
Acadia Pharmaceuticals USD 31.5M 27.86M Jun/2026
Agios Pharmaceuticals USD -99.11M 8.93M Mar/2026
Akebia Therapeutics USD -12.24M 12.78M Dec/2025
Amgen USD 2.38B 556M Jun/2026
AstraZeneca USD 2.51B 573M Jun/2026
Bayer EUR 219M 2.54B Jun/2026
BioMarin Pharmaceutical USD 44.76M 60.76M Jun/2026
Bristol-Myers Squibb USD 3.32B 640M Jun/2026
Cytokinetics USD -198.76M 7.27M Jun/2026
Eisai JPY 18.24B 21.49B Jun/2026
Eli Lilly USD 7.1B 301M Jun/2026
Exelixis USD 212.05M 1.58M Jun/2026
Genmab DKK 303M 250M Jun/2026
Glaxosmithkline GBP 1.74B 890.94M Mar/2026
Incyte USD 585.6M 282.27M Jun/2026
Ionis Pharmaceuticals USD -114.65M 21.65M Jun/2026
MacroGenics USD -36.77M 22.62M Mar/2026
Merck USD -1.34B 2.9B Jun/2026
Moderna USD -1.34B 517M Mar/2026
Nektar Therapeutics USD -44.9M 8.82M Mar/2026
Neurocrine Biosciences USD 144.4M 53.5M Jun/2026
Novartis USD 3.26B 108M Jun/2026
Pfizer USD -248M 2.94B Jun/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Sanofi EUR 1.61B 2.42B Mar/2026
Takeda JPY 113.2B 137.52B Jun/2026
Ultragenyx Pharmaceutical USD -185M 56M Mar/2026
Xencor USD -21.73M 107.19M Jun/2026